Pasritamig

DRUG4 trials

Sponsors

Janssen Research & Development, LLC

Conditions

Metastatic Castration-resistant Prostate NeoplasmsMetastatic Hormone-sensitive Prostate CancerProstatic NeoplasmsProstatic Neoplasms, Castration-Resistant

Phase 1

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

RecruitingNCT05818683

Janssen Research & Development, LLCMetastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer

Start: 2023-04-26End: 2028-05-23Target: 300Updated: 2026-04-01

A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer

RecruitingNCT07319871

Janssen Research & Development, LLCProstatic Neoplasms

Start: 2026-01-14End: 2027-04-30Target: 40Updated: 2026-03-13

Phase 3

A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

RecruitingNCT07164443

Janssen Research & Development, LLCMetastatic Castration-resistant Prostate Neoplasms

Start: 2025-09-02End: 2028-05-30Target: 663Updated: 2025-12-19

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

RecruitingNCT07225946

Janssen Research & Development, LLCProstatic Neoplasms, Castration-Resistant

Start: 2025-12-19End: 2029-07-20Target: 800Updated: 2026-03-13